Mechanistic insights from sequential combination therapy with a sodium glucose co ‐transporter‐2 inhibitor and a dipeptidyl peptidase‐4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Sumie Okahata,
Kentaro Sakamoto,
Takako Mitsumatsu,
Yuko Kondo,
Shoji Tanaka,
Teruo Shiba Source Type: research
More News: Canagliflozin | Diabetes | Eating Disorders & Weight Management | Endocrinology | Invokana | Obesity | Sodium